Skip to content
Search

Latest Stories

'Ethnic minorities less likely to receive optimal end-of-life care within UK healthcare system'

Research indicates that existing policies have disproportionately affected individuals from ethnically diverse groups, leading to unfavourable outcomes

'Ethnic minorities less likely to receive optimal end-of-life care within UK healthcare system'

Ethnic minorities in the UK have experienced disparities in end-of-life care, particularly during the Covid pandemic.

Research indicates that existing policies have disproportionately affected individuals from ethnically diverse groups, leading to unfavourable outcomes, Care Home Professional reported.


Contributing to these disparities is a lack of understanding among healthcare providers about the difference between equal and equitable care, resulting in distress and unequal treatment.

To bridge this knowledge gap and enhance end-of-life care, a team led by Sabrina Bajwah from the Cicely Saunders Institute at King's College London's Faculty of Nursing, Midwifery & Palliative Care has developed an educational film.

The film, funded by the Medical Research Foundation, was collaboratively created with a focus group comprising ethnically diverse patients and health professionals.

The work offers timely guidance to bridge the divide between individuals who receive the best and most comprehensive end-of-life care and those who receive the least and poorest care.

The film, while impactful, remains sensitive in its approach.

It incorporates the voices and experiences of patients, bereaved relatives, and healthcare professionals to foster a deeper understanding of the unique needs of individuals from ethnically diverse backgrounds, the importance of addressing these needs, the distinction between equality and equity, and strategies to deliver equitable care.

Bajwah, the project lead and a clinical senior lecturer, highlights the significance of reducing the gap between the best and worst end-of-life experiences.

Although the research and film primarily focus on ethnically diverse groups, the recommendations for reducing health inequalities are relevant to all underserved populations across different healthcare specialties and settings.

Toby Porter, chief executive of Hospice UK, commends the film as an essential and well-crafted resource.

He emphasises the importance of mandatory viewing among palliative care professionals, as it effectively conveys the need for equitable treatment within the palliative care system.

Porter acknowledges the efforts of hospice colleagues striving for more equitable access to care, underscoring the significance of recognising and addressing existing disparities to drive progress and improvement.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less